CSD/BSE&NSE/PR/2024-2025
April 15, 2024

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400 001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

With reference to above subject, please find enclosed News Release of our company titled **"Suven Life Sciences to present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology (AAN) 2024 Annual Meeting, Denver, USA"**

This is for your information and record.

Thanking You,
Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Digitally signed by Shrenik Soni
Date: 2024.04.15 11:10:19 +05'30'

Shrenik Soni
Company Secretary

Encl: as above

News Release

Suven Life Sciences to present Phase-2 Positive Results on Samelisant (SUVN-G3031) at American Academy of Neurology (AAN) 2024 Annual Meeting, Denver, USA.

Following up to the topline results disclosure earlier, the scientific session scheduled at AAN-2024 will provide the comprehensive findings from the Phase-2 study.

Discussions with Key Opinion Leaders (KOL) and Principle Investigators (PI) at AAN-2024 to finalize the study design for the global Phase-3 study.

Global Phase-3 study initiation expected in the second half of 2024.

Exhibit booth # 742 at AAN-202 is showcasing the Innovations pipeline of Suven Life.

HYDERABAD, INDIA (15-April-2024), Suven Life Sciences, a clinical-stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, announced today scientific presentation at the upcoming 76th American Academy of Neurology (AAN) annual meeting being held April 13-18, 2024, in Denver, USA and virtually. The AAN Annual Meeting is the world's largest gathering of neurologists and neuroscience professionals and offers top-tier education and the latest in scientific discoveries, clinical updates, and many more from around the globe.

Suven's scientific presentation at AAN will highlight details of the positive study results from its Phase-2 proof-of-concept study assessing the safety and efficacy of samelisant for the treatment of excessive daytime sleepiness (EDS) in adult narcolepsy patients with and without cataplexy. The study met primary endpoint, with samelisant demonstrating statistically significant and clinically meaningful reduction in EDS measured by the Epworth Sleepiness Scale (ESS) total score compared to placebo at Day 14 ($p<0.05$). Highly statistically significant effects were observed against placebo for the other efficacy endpoints related to EDS like Clinical Global Impression of Severity (CGI-S) score, Patient Global Impression-Change (PGI-C), and Clinical Global Impression of Change (CGI-C).

AAN 2024 Presentation Details:
Title: Samelisant (SUVN-G3031) – Clinical efficacy and safety outcome from the Phase-2 Proof-of-Concept Double-blind, Placebo-controlled Study in Patients with Narcolepsy.
Presentation on Wednesday, April 17, 2024.

Team of Chief Scientists from Suven will meet several Key Opinion Leaders (KOL), Principle Investigators (PI), Medical and Regulatory advisors at AAN-2024 to discuss the global Phase-3 study design to evaluate Samelisant for the treatment of EDS in adult Narcolepsy patients with and without cataplexy. Global Phase-3 study initiation is expected in the second half of 2024.

Suven is showcasing its innovations pipeline and comprehensive summaries at AAN 2024 with an exhibit booth # 742.

About Samelisant (SUVN-G3031) Phase-2 Study: The Phase-2 clinical study was a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of samelisant as a monotherapy in adult narcolepsy patients with and without cataplexy (ClinicalTrials.gov Identifier: NCT04072380). The study was conducted in USA and Canada and approximately 60 sites participated in this study. The study recruited 190 patients aged 18 to 65 years and were randomized 1:1:1 to 2 mg samelisant, 4 mg samelisant, or placebo treatment groups. The primary efficacy endpoint of this study was change in ESS total score from baseline to Day 14. Secondary and exploratory endpoints were change in CGI-S score, CGI-C score and PGI-C score with regard to EDS and change in Maintenance of Wakefulness Test score from baseline to Day 14.

About Samelisant (SUVN-G3031): Samelisant is a novel, potent, selective, brain penetrant, and orally active Histamine-3 (H3) receptor inverse agonist. H3 receptor blockade elevates histamine, norepinephrine, and dopamine in the brain, a potential for the treatment of EDS and cataplexy. Samelisant exhibited wake-promoting activity in orexin knock-out mice (an animal model of narcolepsy). Pre-clinical in vitro and in vivo efficacy studies, supporting neurochemical studies, pharmacokinetic studies, safety studies and Phase-1 studies in healthy subjects under US IND have been successfully completed for samelisant.

About Suven Life Sciences ("Suven"): Suven is a clinical-stage biopharmaceutical company, focused on discovering and developing novel pharmaceutical products, for CNS disorders. Our focus has been on the discovery and development of innovative molecules targeting diseases and areas, which has undiscovered medical treatment opportunities. Suven singularly focuses on the development of "New Chemical Entities" ("NCEs") molecules for CNS diseases such as Alzheimer's, various forms of Dementia, Narcolepsy, Major Depressive Disorder ("MDD"), Attention Deficient Hyperactivity Disorder ("ADHD"), Huntington's disease, Parkinson, Bipolar disorder and different forms of neuropsychiatry disorders, gastrointestinal disorders, and pain disorders. Suven has 7 clinical-stage compounds, Masupirdine (SUVN-502) for treatment of agitation in patients with dementia of the Alzheimer's type (Phase-3 ongoing), Samelisant (SUVN-G3031) for sleep disorders (Phase-2 completed), Ropanicant (SUVN-911) for Major Depressive Disorder (Phase-2 ongoing) and Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 ready) and 3 other compounds in early stages of clinical development. In addition to clinical candidates, Suven has 8 molecules in the development pipeline.

For more information please visit our website at http://www.suven.com

Risk Statement: Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.